



Investor Presentation

Medicamen Biotech Limited



Committed for **affordable quality**
through **improvement and technology**

Safe Harbour Statement

This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements. These factors include, but are not limited to, domestic and global economic and business conditions, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, etc. As a result, MBL’s actual future results may differ materially from the plans, goals and expectations set forth in such forward looking statements. MBL does not undertake any obligation to update such forward looking statements to reflect events or circumstances after the date thereof.

Medicamen Biotech Limited – An overview

An Overview of Company



- Medicamen Biotech was established in 1996 and is engaged in manufacturing of diverse range of pharmaceutical products Oral Solids, Oral Liquids, ointment for non-oncology products range and it also produces tablet, capsule/lyophilized/dry powder injections for oncology product range.
- MBL has three state of art manufacturing facility is located at Bhiwari (Rajasthan) and two of its plants are located at Haridwar (Uttarakhand).
- Bhiwadi Plant is spread over in a sprawling area of 20625 sqm, having approx. 12000 sqm of constructed area divided into 8 different blocks.
- Bhiwadi Plant is “WHO” GMP approved, and ISO certified.
- Medicamen has its second plant at SIDCUL Haridwar, for domestic market. This plant has recently got WHO GMP Certification. The plant has been audited by Ethiopian Authorities in the month of June has got approval on 4th August 2022. This plant is basically for Ointment and Cream.
- Medicamen has set up its third State of Art ONCOLOGY FORMULATIONS Plant at Haridwar which has started the commercial production from this year. This plant has recently got WHO GMP Certification. This plant is USFDA compliant and aims to cater to regulated market like US, EU, UK and Japan etc.

Medicamen Biotech Limited



Current Business

- **MBL's Bhiwadi plant is approved in more than 30 countries having around 125 product registrations.**
- **Currently company is working with over 150 SKU across 20 different therapeutic segments.**
- **Top Therapeutic segments include Antibiotics, Antifungal, Anti pain management, Analgesics and Anti malaria, forming around 80% of Revenue.**
- **Currently MBL is into exports only, 80% of Revenue comes from Direct Exports and rest comes from merchant Exports. The majority of the revenue is from African region, Latin America and Southeast Asia.**

Global Presence



Future Growth Plan – Oncology Segment

- Started ethical marketing of the Oncology products in India with a team of 25 senior executives in four zones.
- MBL has launched three Oncology products in the month of January, and it has already launched eight products as on date.
- MBL has plans to file two ANDA's during the current financial year.
- Targeted market for Oncology would be regulated as well as semi regulated markets.

For the use of registered medical practitioner, laboratory or hospital only.

VIVO Oncology
Quality Cancer Care

ABTmed™
Hetero Labs Ltd

PROSTATE CANCER

Child-Resistant Packaging

State-of-the-Art Manufacturing Facilities dedicated for Oncology, APIs & Formulations, compliant to cGMP, USFDA, EU GMP

Global Quality Standards

Ensuring Patient Safety

Global presence in more than 35 countries

Radiamed™
Unilabs Research

SUPPORTIVE CARE

Transforming Lives... Through Quality

MBL MEDICAMEN Biotech Limited

Corporate office & Regd. office:
208, Changan Road, 4th Floor, New Delhi - 110005, India
Ph. No. +91 11 2626542 / +91 11 2626503
E-mail: global.oncology@medicamen.com & info@medicamen.com
Website: www.medicamen.com www.ab-vaik-rasagar.com

Future Growth Plan – Product Profile

For Hand Foot Syndrome

VIVO Oncology
Quality Cancer Care

INTRODUCING

Rx Radiamed™
Urea, Lactic Acid & Glycerin Cream
Cream
Safe, Effective & Affordable

Improves QoL and Aids cancer patients continue chemotherapy



VIVO Oncology
Quality Cancer Care


In metastatic NSCLC & locally advanced Pancreatic Cancer

INTRODUCING

Rx ETBmed™
Erlotinib Tablets IP 100 mg / 150 mg
Effectively Blocks EGFR

Patients who received chemotherapy with erlotinib and achieved major pathological responses had excellent clinical outcome¹

Ref: 1. Clin Cancer Res clincanres.3239. 2021



Future Growth Plan – Product Profile


INTRODUCING
In DTC, HCC, RCC
& Endometrial Cancer

Lenvamed™
Lenvatinib Capsules 4 mg / 10 mg

LIFTING HOPE

Indications

- Differentiated Thyroid Carcinoma (DTC)
- Renal Cell Carcinoma (RCC)
- Unresectable Hepatocellular carcinoma (HCC)
- Endometrial Cancer



INTRODUCING
In the treatment of advanced or
metastatic renal cell carcinoma (mRCC)

PAZOCAM™
Pazopanib Hydrochloride Tablets 200 mg / 400 mg

Prolongs Life

Future Growth Plan – Product Profile

INTRODUCING

Rx **Capivo**TM

Carrying Hope

Capecitabine Tablets IP 150 mg / 500 mg



In the treatment of Multiple Myeloma
& Mantle Cell Lymphoma

Rx **Borzomed**TM

Bortezomib Injection 2 mg / 2.5 mg / 3.5 mg per vial

Bringing life to life



Future Growth Plan-Marketing Network in Africa

- MBL intends to create its own marketing network in ten Francophone countries by using distributing network of Euro Pharma, Paris which holds 11% equity in MBL.
- MBL intends to market 100 branded products in this territory for which the brands have been finalized.
- MBL has a target to file 100 dossiers in each of ten francophone countries making total 1000 dossier in all.

- 
- MBL has already recruited a senior executive who is based in Ghana, the marketing companies have also been shortlisted, who will handle its marketing operation in these Francophone countries.
 - Currently MBL has 23 registered products in Ethiopia and is aiming to register 100 products by this financial year end.
 - Apart from this MBL is also filing dossiers in Zimbabwe, Tanzania.

Thank you!

Medicamen Biotech Limited

REGISTERED OFFICE

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019

Phone 011-47589500 (30 Lines) | **Fax** 011-26213081 | **E-mail** cs@medicamen.com

Website www.medicamen.com